Tesaro Inc.'s Zejula (niraparib) may be the third PARP inhibitor to the US market, but it is positioned to seize the first-mover advantage for maintenance treatment of ovarian cancer, following a broad FDA approval for this indication, regardless of mutation status and without the need for a companion diagnostic.
Approval for the poly ADP-ribose polymerase inhibitor was announced March 27, well ahead of the drug's June 30 user fee...